An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1875-6417|8|3|169-182

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.8, Iss.3, 2012-05, pp. : 169-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors

By  

Current Diabetes Reviews, Vol. 4, Iss. 2, 2008-05 ,pp. : 101-109

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach

By Dai Yao   Dai Dongsheng   Mercanti Federico   Ding Zufeng   Wang Xianwei   Mehta Jawahar  

Acta Diabetologica, Vol. 50, Iss. 6, 2013-12 ,pp. : 827-835

Springer Publishing Company

Access to resources Recommend Favorite

Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus

By  

Current Diabetes Reviews, Vol. 7, Iss. 5, 2011-09 ,pp. : 325-335

Bentham Science Publishers

Access to resources Recommend Favorite

Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 10, Iss. 4, 2012-12 ,pp. : 276-288

Bentham Science Publishers

Access to resources Recommend Favorite

Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance

By  

Current Diabetes Reviews, Vol. 9, Iss. 5, 2013-09 ,pp. : 412-417

Bentham Science Publishers

Access to resources Recommend Favorite